In an article written by Zinger et al. 2021 from the Center for Musculoskeletal Regeneration at the Houston Methodist Research Institute, the challenge of reproducible and scalable therapeutic drug delivery with high cell specificity to neural cells was investigated through analysis of biomimetic nanovesicle (neurosomes) physiochemical properties. Neurosomes synthesized by NanoAssemblr ® microfluidic based technology are liposomes that contain membrane proteins, such as NCAM1, sourced from human pluripotent stem-cell (hSPC) neurons. Consistency in particle morphology, size, and homogeneity alongside high customizability in modulating protein:lipid ratios contributed to an increase uptake in neurosomes into cultured neurons as highlighted by the paper. Further administration of the neurosomes in vitro using organoid-based spheres originated from cultured hPSC-derived iNeurons, and in vivo using rodent trigeminal ganglion cells resulted in higher association of neurosomes with the respective cells. This result is indicative of higher neural targeting when compared to non-protein liposomes which may play an essential role in future developments with delivery of specific therapeutic cargoes, such as, neural growth factors for outgrowth or synaptic connectivity to address a wide range of neurological diseases.